BrioHealth Solutions, a US-based company developing the BrioVAD System, a Left Ventricular Assist Device (LVAD), announced on Monday that the 100th participant has been enrolled in the system's INNOVATE Trial.
Launched in late 2024, the INNOVATE Trial is a national research study to evaluate an innovative mechanical heart pump designed to help patients whose hearts can no longer pump enough blood on their own. The trial aims to evaluate the BrioVAD System to develop more reliable and longer-lasting devices that can improve both survival and quality of life.
The BrioVAD System is designed to augment blood flow, enhance patient comfort, and minimise complications, while prioritising patient well-being and reduce the occurrence of adverse events associated with advanced heart failure treatment.
Ipsen licenses Simcere Zaiming antibody-drug conjugate for global development
Shield Therapeutics wins FDA approval to expand ACCRUFeR use to adolescents
Hansa Biopharma submits imlifidase Biologics License Application to FDA
T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM
Ipsen closes Phase II FALKON trial after missing primary endpoint in FOP
Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
PRISM BioLab partners with Talus Bioscience to address TF and PPI targets
Thryv Therapeutics reports positive Phase 1 results for THRV-1268